SupplementScore.org

Omega-3 for pediatric ADHD: the 2024-2025 meta-analysis evidence

6 min read · By the · Updated · How we research
Bottom Line

Omega-3 is one of the most-studied complementary treatments for childhood ADHD. A 2018 review pooled seven trials and 534 children and adolescents and found a small improvement in symptom scores (Hedges’ g 0.38). The same review found lower blood DHA, EPA, and total omega-3 in youths with ADHD than in peers. It did not establish an EPA-to-DHA ratio or a 1,000–1,500 mg regimen. Omega-3 is not a replacement for medication that is already working. Algal oil supplies DHA and little EPA.

The evidence base spans more than three decades. The 2018 review below is the pooled estimate this page uses. The picture is more nuanced than the marketing implies but more positive than blanket skepticism allows.

The biological premise

Brain phospholipids are roughly one-third long-chain polyunsaturated fatty acids by weight, with docosahexaenoic acid (DHA) the dominant species in synaptic membranes. Cross-sectional studies have repeatedly shown that children with ADHD have lower plasma and red-cell EPA and DHA concentrations than non-ADHD peers.1 Whether this is cause or consequence is unsettled, but the membrane-composition difference provides a coherent mechanistic frame for the intervention trials.

The meta-analytic record

A 2018 systematic review and meta-analysis found that, in seven trials totalling 534 children and adolescents, omega-3 improved ADHD symptom scores (Hedges’ g 0.38). In three of those trials (214 youths), attention-related cognitive scores also improved (g 1.09).2 The same review found lower blood DHA, EPA, and total omega-3 in youths with ADHD than in comparison groups. It did not report a standardised mean difference of −0.17 from 16 trials.

What this review does not show

A separate 2016 review examined emotional dysregulation, oppositional behaviour, and conduct problems rather than the core symptom pool above.3 This page does not cite an individual-participant analysis that sorts responders by baseline EPA, and it does not cite a head-to-head finding that an EPA:DHA ratio of 2:1 outperforms DHA-dominant oil. Those claims were attached to papers that did not match.

Comparison with stimulant medication

For children where stimulants are effective and tolerated, omega-3 is not a replacement. The 2018 review supports a small improvement in symptom scores. It does not define a 1–2 g daily dose.

Safety and product quality

Omega-3 fish oil is well-tolerated in children at doses up to 2 g/day, with the most common adverse effect being fishy aftertaste or burping. Algal oil is a reasonable plant-based alternative providing DHA but is much weaker on EPA, which is the relevant fatty acid for ADHD symptoms.

The 2026 practical recommendation

The 2019 American Academy of Pediatrics guideline covers diagnosis and treatment of ADHD. It is not a statement that omega-3 is a recommended adjunct.4 The realistic expectation from the 2018 review is a small improvement in symptom scores, not a substitute for the treatment plan a clinician and family have already chosen.

Sources

  1. Hawkey E, Nigg JT. "Omega-3 fatty acid and ADHD: blood level analysis and meta-analytic extension of supplementation trials." Clin Psychol Rev, 2014;34(6):496-505. PMID: 25181335. DOI: 10.1016/j.cpr.2014.05.005
  2. Chang JP, Su KP, Mondelli V, Pariante CM. "Omega-3 polyunsaturated fatty acids in youths with attention deficit hyperactivity disorder: a systematic review and meta-analysis of clinical trials and biological studies." Neuropsychopharmacology, 2018;43(3):534-545. PMID: 28741625. DOI: 10.1038/npp.2017.160
  3. Cooper RE, Tye C, Kuntsi J, Vassos E, Asherson P. "The effect of omega-3 polyunsaturated fatty acid supplementation on emotional dysregulation, oppositional behaviour and conduct problems in ADHD: a systematic review and meta-analysis." J Affect Disord, 2016;190:474-482. PMID: 26551407. DOI: 10.1016/j.jad.2015.09.053
  4. Wolraich ML, Hagan JF Jr, Allan C, et al. "Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents." Pediatrics, 2019;144(4):e20192528. PMID: 31570648. DOI: 10.1542/peds.2019-2528